论文部分内容阅读
目的探讨非清髓性异基因外周血造血干细胞移植治疗低增生性骨髓增生异常综合征(MDS)的疗效,观察其植入及并发症的发生情况。方法我院诊断为低增生性MDS患者1例,采用氟达拉滨+阿糖胞苷+环磷酰胺的非清髓预处理方案,环孢素A+甲氨蝶呤+骁悉预防移植物抗宿主病。结果 STR-PCR证实移植后30d及3个月骨髓植入为完全供者型,移植后3个月发生多发性脑梗塞,6个月出现面部皮疹及口腔溃疡,通过调整免疫抑制剂及输注间充质干细胞(5×107/次,2次)后症状明显好转。结论非清髓性异基因外周血造血干细胞移植治疗低增生性MDS获得较好的疗效。
Objective To investigate the efficacy of non-myeloablative allogeneic peripheral blood stem cell transplantation in the treatment of hypo-proliferative myelodysplastic syndrome (MDS) and to observe the incidence of complications and its complications. Methods One patient with hypo-proliferative MDS diagnosed in our hospital was treated with fludarabine + cytarabine + cyclophosphamide non-myeloablative preconditioning regimen. Cyclosporine A + methotrexate + Host disease. Results The results of STR-PCR showed that the bone marrow was completely donated at 30 days and 3 months after transplantation. Multiple cerebral infarction occurred 3 months after transplantation and facial rash and oral ulcer occurred at 6 months. By adjusting immunosuppressive agents and infusion Mesenchymal stem cells (5 × 107 / times, 2 times) after the symptoms improved significantly. Conclusion Non-myeloablative allogeneic peripheral blood stem cell transplantation for the treatment of hypo-proliferative MDS obtained better curative effect.